Filing Details

Accession Number:
0001209191-14-023493
Form Type:
4
Zero Holdings:
No
Publication Time:
2014-03-27 17:10:57
Reporting Period:
2014-03-26
Filing Date:
2014-03-27
Accepted Time:
2014-03-27 17:10:57
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1513818 Versartis Inc. VSAR Pharmaceutical Preparations (2834) 244106690
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1601363 Advent Life Sciences Fund I Lp 158 North Gower Street
London X0 NW1 2ND
No No Yes No
1601364 Llp Sciences Life Advent 158 North Gower Street
London X0 NW1 2ND
No No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2014-03-26 1,258,086 $0.00 1,258,086 No 4 C Indirect See FN
Common Stock Acquisiton 2014-03-26 489,253 $0.00 1,747,339 No 4 C Indirect See FN
Common Stock Acquisiton 2014-03-26 176,813 $0.00 1,924,152 No 4 C Indirect See FN
Common Stock Acquisiton 2014-03-26 78,228 $0.00 2,002,380 No 4 C Indirect See FN
Common Stock Acquisiton 2014-03-26 154,178 $0.00 2,156,558 No 4 C Indirect See FN
Common Stock Acquisiton 2014-03-26 60,000 $21.00 2,216,558 No 4 P Indirect See FN
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 C Indirect See FN
No 4 C Indirect See FN
No 4 C Indirect See FN
No 4 C Indirect See FN
No 4 C Indirect See FN
No 4 P Indirect See FN
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Series B Convertible Preferred Stock Warrants to Purchase Series B Preferred Stock Disposition 2014-03-26 506,376 $0.00 506,376 $0.45
Common Stock Series B Convertible Preferred Stock Acquisiton 2014-03-26 506,376 $0.00 44,031 $0.00
Common Stock Series B Convertible Preferred Stock Disposition 2014-03-26 14,468,020 $0.00 1,258,086 $0.00
Common Stock Series C Convertible Preferred Stock Disposition 2014-03-26 5,626,413 $0.00 489,253 $0.00
Common Stock Series D-1 Convertible Preferred Stock Disposition 2014-03-26 2,033,350 $0.00 176,813 $0.00
Common Stock Series D-2 Convertible Preferred Stock Disposition 2014-03-26 899,619 $0.00 78,228 $0.00
Common Stock Series E Convertible Preferred Stock Disposition 2014-03-26 1,773,049 $0.00 154,178 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 2014-03-26 No 4 X Indirect
14,468,020 No 4 X Indirect
0 No 4 C Indirect
0 No 4 C Indirect
0 No 4 C Indirect
0 No 4 C Indirect
0 No 4 C Indirect
Footnotes
  1. In connection with the completion of the Issuer's initial public offering of Common Stock, each share of Series B Convertible Preferred Stock, Series C Convertible Preferred Stock, Series D-1 Convertible Preferred Stock, Series D-2 Convertible Preferred Stock and Series E Convertible Preferred Stock automatically converted into Common Stock on a 1-for-11.5 basis.
  2. Securities are held by Advent Life Sciences LLP ("Advent") and Advent Life Sciences Fund I LP ("Advent Fund"). Advent is the general partner of Advent Fund.
  3. Immediately exercisable. In connection with the closing of the Issuer's initial public offering of Common Stock the warrant to purchase Series B Convertible Preferred Stock shall automatically convert into a warrant to purchase Common Stock on a 1-for-11.5 basis if the warrant is not otherwise exercised prior to such closing.
  4. The securities do not have an expiration date. Each share of Series B, Series C, Series D-1, Series D-2 and Series E Convertible Preferred Stock converted automatically into shares of Common Stock in connection with the closing of the Issuer's initial public offering on March 26, 2014. Prior to its conversion into the Issuer's Common Stock, The Series B, Series C, Series D-1, Series D-2 and Series E Convertible Preferred Stock was convertible at any time at the option of the holder.